"I'm a physician who took 5 Lariam tablets ... was never advised of the side effects ... am way off cognitively ... can't focus ... having severe anxiety episodes ... feel totally dysfunctional ... sick sense that this may be a permanent problem. I wish there was something I could do."

Drug Label and Safety Information

Sandoz - prescribing information for generic mefloquine

Product Information Update - 2008 (PDF)

Summer 2008 FDA Newsletter: warning about Lariam and pheumonitis

Previous Lariam Product Information - Roche (PDF), May 2004

Lariam official product information, with new Consumer Medication Guide, August 2003 (PDF). (FDA regulation 21CFR 208 requires a Medication Guide to be provided with each prescription that is dispensed for products that FDA determines pose a SERIOUS and SIGNIFICANT PUBLIC HEALTH CONCERN. [emphasis added])

"Dear doctor" letter, September 2003 (PDF)

FDA press release about Consumer Medication Guide, July 2003

"Dear doctor" letter, announcing addition of suicide and new contraindications and warnings to Lariam product information, September 2002 (PDF)

2002 Lariam label, with changes from 1999 highlighted (PDF)

Lariam Product Information, Roche USA, revised August 1999 (PDF)

World Health Organization: Review of Central Nervous System Adverse Events Related to the Antimalarial Drug, Mefloquine (1985 -1990), a joint report by WHO and the Drug Safety Unit, Hoffmann-La Roche, 1991.

APRIL, Adverse Psychiatric Reactions Information Link,Mailing Address: APRIL, PO Box 2082, Woodford Green, Essex IG8OGS, England email: info@april.org.uk